Journal
CELL SYSTEMS
Volume 8, Issue 4, Pages 345-+Publisher
CELL PRESS
DOI: 10.1016/j.cels.2019.03.011
Keywords
-
Categories
Funding
- Canadian Institute of Health Research [MOP-133615]
- CIHR Frederick Banting
- Charles Best Doctoral Research Award
Ask authors/readers for more resources
High-grade serous ovarian carcinoma (HGSC) is the most common and lethal subtype of gynecologic malignancy in women. The current standard of treatment combines cytoreductive surgery and chemotherapy. Despite the efficacy of initial treatment, most patients develop cancer recurrence, and 70% of patients die within 5 years of initial diagnosis. CA125 is the current FDA-approved biomarker used in the clinic to monitor response to treatment and recurrence, but its impact on patient survival is limited. New strategies for the discovery of HGSC biomarkers are urgently needed. Here, we describe a proteomics strategy to detect tumor-associated proteins in serum of HGSC patient-derived xenograft models. We demonstrate proof-of-concept applicability using two independent, longitudinal serum cohorts from HGSC patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available